Increased Risk of Brain Metastases Among Patients with Melanoma and PROM2 Expression in Metastatic Lymph Nodes

Thuy Thi Nguyen  
National cancer hospital

Guillaume Gapihan  
Universite Paris Diderot

Pauline Tetu  
Assistance Publique - Hopitaux de Paris

Frédéric Pamoukdjian  
Université Paris 13

Morad El Bouchtaoui  
Universite Paris 13

Christophe Lebœuf  
Universite Paris Diderot

Jean-Paul Feugeas  
Universite de Franche-Comte

Justine Paris  
INSERM

Barouyr Baroudjian  
Assistance Publique - Hopitaux de Paris

Julie Delyon  
Assistance Publique - Hopitaux de Paris

Samia Mourah  
Universite Paris Diderot

Céleste Lebbé  
Universite Paris Diderot

Anne Janin  
Universite Paris Diderot

Guilhem Bousquet (✉ guilhem.bousquet@aphp.fr)  
University Paris 13  https://orcid.org/0000-0001-5594-6694

Maxime Battistella  
Universite Paris Diderot

Research

Keywords: brain metastases, melanoma, PROM2

DOI: https://doi.org/10.21203/rs.3.rs-56318/v1
Abstract

Background: Melanoma brain metastases are the main cause of specific death among patients with metastatic melanoma. The biology of melanoma brain metastases remains largely to be deciphered, as there have been only a few genomic studies on brain metastatic samples. In this study, melanoma metastatic lymph nodes were used with the aim to identify biomarkers associated with the occurrence of brain metastases.

Methods: Fifty-one patients with melanoma lymph node metastasis and a median follow-up of 48 months were included in the development cohort. Transcriptomic data were obtained from these metastatic lymph nodes and patients who developed brain metastases and those who did not were compared. Recommendations for tumour marker prognostic studies (REMARK recommendations) were followed.

Results: From transcriptomic data, we identified PROM2 which was significantly overexpressed in metastatic lymph nodes of patients who developed brain metastases compared to those who did not. Using immunohistochemistry with two different anti-PROM2 antibodies, a PROM2 score was developed for metastatic lymph nodes. Using a cut-off of 5, a PROM2 mean score $\geq 5$ was significantly associated with an increased risk of brain metastases and an increased hazard risk of death by 4.

These results were confirmed in an internal validation cohort of 50 additional patients with melanoma lymph node metastases.

Conclusions: In this study, we identified PROM2 expression as a biomarker predictive of the occurrence of distant metastases, particularly brain metastases, among patients with stage III melanoma. Our findings open new perspectives to validate PROM2 as a useful biomarker for clinical trials in the adjuvant setting, and as a potential biotarget for the treatment of metastatic melanoma.

Background

Melanoma is an increasing cause of death by cancer, due to an increased incidence of metastases and particularly brain metastases. Brain metastases occur in the progression of metastatic melanoma in up to 44% of cases (1, 2). In addition, the incidence of brain metastases has increased in the last ten years as a result of better control of localizations outside the central nervous system with immunotherapies (3, 4), and because most anti-cancer drugs fail to cross the blood-brain barrier at relevant pharmacological concentrations (5). Despite evidence of clinical benefit of combined immunotherapies on melanoma brain metastases (6), more than 50% of patients will have brain progression, challenging daily practice in oncology.

The biology of melanoma brain metastases remains largely to be deciphered, mainly due to difficult access to tissue samples. There have been few genomic studies on melanoma brain metastases, and most of them have explored their mutational status, comparing brain metastases with matched primary melanoma or extra-central nervous system metastases (7–9). There are even less transcriptomic data on melanoma brain metastases, characterized by an activation of the PI3K pathway (7, 10). In a transcriptomic study on soft tissue, skin or lymph node metastases, PLEKHA5, a pleckstrin homology domain-containing protein family A, member 5, was identified as a potential biomarker predictive of the risk of melanoma brain metastases (11).

In our study, we performed transcriptomic analyses on laser-micro-dissected tumour cells from metastatic lymph nodes of patients with metastatic melanoma. Clinical follow-up enabled us to compare molecular results for patients
who developed brain metastases and for those who did not. Our aim was to identify biomarkers associated with the occurrence of brain metastases over a median follow-up of 48 months, and assess their association with survival.

**Methods**

We have followed reporting recommendations for tumour marker prognostic studies (REMARK recommendations) (12).

Some methods are fully detailed in Supplementary Material and Method file.

**Patient data**

One hundred and one patients from Saint-Louis Hospital with available tumour samples and follow-up data were included in this study, for the development and the validation cohorts. Informed consent was obtained from each patient. The Clinical-Research-Board-Ethics-Committee approved this study (CPP-Ile-de-France#13218).

All patients were diagnosed between 2009 and 2014, and had a regional macroscopic lymph node metastatic melanoma without distant metastases at the time of inclusion in this study. None of them received systemic adjuvant therapy. Fifty-one patients were included in the development cohort, with samples collected between 2009 and 2013. Fifty additional patients were included in the validation cohort, with samples collected between 2013 and 2014.

On the basis of clinical and imaging data, and a median follow-up of 48 months from the time of the regional lymph node disease, patients with and without distant metastases were separated, including those with brain metastases. As recommended by the National Comprehensive Cancer Network, magnetic resonance imaging (MRI) of the brain was systematically performed at the time of the metastatic disease, and then at least once a year, or in case of neurological symptoms.

**Laser-microdissection of tumour cells from metastatic lymph nodes and transcriptomic data processing**

For the development cohort, we identified 336 patients with melanoma and regional lymph node metastatic samples collected between 2009 and 2013. Among them, 100 patients had at least one frozen metastatic sample available and 58 patients had a follow-up of at least 36 months from diagnosis of metastatic disease (Supplementary Fig. 1). Cryo-cut sections of each sample were laser-micro-dissected to select tumour cells. Using a PALM-Microbeam/Zeiss system, a minimum of 1500 tumour cells were laser-micro-dissected for RNA extraction. 51 cases had a mean RNA integrity number of 8.7 (range 7-10) (Supplementary Fig.1).

Transcriptomic analyses were performed using MiltenyiBiotec-Microarray.

**RT-qPCR and validation of PROM2 mRNA expression in metastatic lymph-nodes**

For the development cohort, on following sections of the same laser-micro-dissected metastatic lymph nodes, RT-qPCR was performed to validate the transcriptomic results for PROM2 expression, according to the MIQE guidelines(13).

For the validation cohort, melanoma cancer cells from 50 metastatic lymph nodes were laser-micro-dissected and processed for RT-qPCR.

**In situ** PROM2 expression in metastatic lymph nodes
Using immunochemistry, PROM2 expression was assessed in the metastatic lymph nodes of the 101 samples of the two cohorts. An indirect immuno-peroxidase method (Discovery/RocheDiagnostics) on 5µm-thick frozen tissue sections was used using anti-PROM2 (ab74997, rabbit polyclonal, Abcam, 1/100) as primary antibody, and anti-rabbit OmniMap detection kit (Roche-Diagnostics). Systematic controls were the absence of a primary antibody and the use of an irrelevant primary antibody of the same isotype. Normal skin and normal liver were used as positive and negative controls respectively. A membranous and cytoplasmic distribution of PROM2 was considered positive. Each sample was given a score by multiplying the stain intensity grade (0 = no staining, 1 = low intensity, 2 = medium intensity, 3 = strong intensity) by the numerical code for the percentage of positive cells (0 = 0%, 1 = under 10%, 2 = 10–50%, 3 = 51–80%, 4 = over 81%).

Statistical analyses

The data were analyzed using R statistical software (version 3.4.3, R Foundation for Statistical Computing, Vienna, Austria; http://www.r-project.org).

Transcriptomic data: The SAMR package was used to identify differentially expressed genes in samples with the two-class unpaired method.

We performed the same analyses on transcriptomic data downloaded from public databanks (14),(15),(16),(11).

Factors associated with brain metastases: Patients with and without brain metastases were compared regarding their clinical and biological characteristics. Univariate and multivariate logistic regression were performed with the sample of brain metastatic patients.

Factors associated with mortality: Univariate survival curves were plotted according to the Kaplan-Meier method for brain metastatic status, and "PROM2 IHC score". Univariate and multivariate Cox proportional hazard regression were performed with the sample of patients deceased.

Results

Patient characteristics in the development cohort

Among the 51 patients selected for this study, after a median follow-up of 48 months from the time of regional lymph node disease, 19 (37%) developed brain metastases while 32 (63%) did not. The characteristics of these 51 patients are summarized in Table 1, comparing patients with brain metastases (Group 3) and patients without (Groups 1 and 2) (Fig.1A).

Each metastatic lymph node was laser-micro-dissected to specifically select a minimum number of 1500 tumour cells, with a mean surface area of 645 000 µm² ± 175 000µm². After RNA extraction, all samples were of good quality, enabling transcriptomic analyses, since the mean RNA integrity number was 8.7 (range 7–10).

The median overall survival calculated from first diagnosis of regional lymph node metastasis was significantly shorter among patients with brain metastases than among patients without brain metastases (39 months vs. 76 months, p<0.01) (Fig. 1B). The median survival from the time of brain metastases was 13.3 months (range 2-72 months). Among patients with BRAFV600E mutation, the median survival was not significantly different for patients with and without brain metastases (14 vs. 17 months).

PROM2 gene expression in metastatic lymph nodes from patients with brain metastases
Transcriptomic analyses were performed on laser-micro-dissected tumour cells obtained from metastatic lymph nodes of the 51 patients. Multivariate analysis was carried out to compare data from patients with brain metastases and those without. Table 2 shows the genes with the highest d-scores and fold-changes, all of them having a Q-value <0.001. We decided to focus on the PROM2 gene, also called prominin-2, with some of the highest d-scores at 4.6 and fold-change of 3.3, and because the PROM2 protein induces membrane protrusions (17) and could thus be implicated in invasive processes.

Using RT-qPCR, we confirmed that the median expression of PROM2 mRNA was significantly higher in metastatic lymph nodes from patients who subsequently developed brain metastases (ΔCt= 4.9, IQR=6.3) than in those from patients who did not (ΔCt= 2.1, IQR=3.9) (p = 0.005, Fig. 2A).

We then analysed transcriptomic data downloaded from public databanks. In 167 metastatic lymph nodes of the TCGA SKCM cohort, a high PROM2 expression was found to be associated with poor survival (p=0.007, score logrank test = 7.15) (Supplementary Fig.2A). In the GSE cohorts that were used to construct Lund molecular classification (GSE22155 and GSE65904) (15, 16), a high PROM2 expression level in 102 metastatic lymph nodes tended to be associated with a poor survival in the first 1000 days of follow-up (score logrank test = 2.99, p=0.08) (Supplementary Fig.2B).

**PROM2 protein expression in metastatic lymph nodes is associated with the risk of brain metastases**

Using immunohistochemistry, PROM2 expression was assessed on the 51 metastatic lymph nodes. We showed that the PROM2 was only expressed by cancer cells and that the mean “PROM2 IHC score” was significantly higher among patients with brain metastases compared to patients without (8.8 vs. 4, p<0.01) (Fig. 2B).

When we chose a cut-off of 5 for the “PROM2 IHC score”, overall survival was significantly longer among patients who had a score <5 than among patients who reached the cut-off of 5 (p < 0.01, Figure 2C).

Overall, PROM2 expression in metastatic lymph nodes from melanomas is associated with the risk of brain metastases and with decreased survival.

**PROM2 expression is low in regional lymph nodes without associated distant metastases**

We also compared PROM2 protein expression and overall survival across the three groups, and found that the “PROM2 IHC score” differed gradually and significantly across the 3 groups (Fig. 3B). Overall survival was also much longer for Group 1 with only metastatic regional lymph nodes and without distant metastases after a median follow-up of 80 months (Fig. 3C).

Risk factors for brain metastasis were identified first by univariate analysis and then by multivariate analysis. Using multivariate regression, we identified a “PROM2 IHC score” ≥ 5 and the presence of bone metastases as the two variables significantly associated with the risk of brain metastases. For the “PROM2 IHC score”, the odds ratio was particularly high, at 28.2 (p=0.003, Table 3), showing the strongest association with the risk of developing brain metastases.

Among patients with resectable regional lymph node metastases and stage III melanoma, an elevated “PROM2 IHC score” enabled identification of a high-risk group for distant metastases, including brain metastases.

**Validation cohort confirms PROM2 as a biomarker for distant metastasis**
Between 2013 and 2014, 50 additional patients with stage III melanoma at diagnosis and a frozen biopsy sample from lymph node metastases were included in this validation cohort. After a median follow-up of 48 months from the time of the regional lymph node disease, 19 patients (38%) developed brain metastases while 31 (62%) did not. There was no significant difference between the development and the validation cohorts for clinical characteristics or melanoma features (Supplementary Table 1).

In this validation cohort, when PROM2 mRNA expression was assessed on melanoma cancer cells laser-micro-dissected from metastatic lymph nodes, it was significantly higher among patients who developed brain metastases (median ΔCt=5.1, IQR=2.3) than among patients who did not (median ΔCt=2, IQR=4.6) ($P<0.01$). The “PROM2 IHC score” was also significantly higher in case of brain metastases (7.4 vs. 2.1, $P<0.01$). Using a cut-off of $\geq 5$ for the “PROM2 IHC score” in multivariate regression, the “PROM2 IHC score” was the only factor associated with the risk of brain metastases.

In the two cohorts, in univariate analysis, a high “PROM2 IHC score” $\geq 5$ in metastatic lymph nodes was not associated with the risk of other metastatic sites (lung, liver, bone), except for lung metastases in the validation cohort (Supplementary Table 2).

In both the development and validation cohorts, the presence of brain metastases and a “PROM2 IHC score” of $\geq 5$ were the only two factors significantly associated with mortality (Table 4 and Supplementary Figure 3).

**Discussion**

In this study, among patients with regional lymph node metastases from cutaneous melanoma, we identified PROM2 as a biomarker significantly associated with the risk of distant metastases, particularly brain metastases.

Multivariate analysis showed that the high “PROM2 IHC score” in metastatic lymph nodes and the occurrence of bone metastases were the only two factors significantly associated with the risk of brain metastases. In a large observational study of 26,430 cancer patients with brain metastases, bone and lung metastases were more frequently associated with the risk of brain metastases than were liver metastases (1). In the case of lung metastases, cancer cells can enter the pulmonary vein through the lung capillaries, taking cancer cells into the arterial circulation via the left ventricle, and thus favoring the development of brain metastases (18). This preferential association of lung or bone metastases with brain metastases is particularly true for melanoma. This could be explained by the short median survival of 4 months in case of liver metastases (1, 19) while the median time lapse to the appearance of brain metastases is 9 months (20). There could also be biological reasons, such as the expression of chemokine receptor in melanoma cells and of its respective ligand in a target site for metastasis (21, 22). It still remains unclear whether the expression of chemokine/chemokine-receptors contributes to a preferential distribution of melanoma metastases in the brain.

In our large series of 101 frozen metastatic lymph nodes, the “PROM2 IHC score” was the strongest marker associated with the development of distant metastases in melanoma patients, particularly brain metastases, and with a shorter survival. In two large series of metastatic lymph nodes, a high PROM2 expression was found to be associated with poor survival (14–16). In another small series of 14 metastatic lymph nodes, no association was found between PROM2 expression level and the occurrence of brain metastases (11). This association between a high PROM2 expression in metastatic lymph nodes and a pejorative evolution is strength of our study, with potential translational applications among patients with stage III melanoma. Indeed, adjuvant treatment using immunotherapy or targeted anti-BRAF and anti-MEK therapies is recommended for patients with stage III disease. No other marker than regional lymph node involvement is currently included in the therapeutic decision. In our study, we were able to
identify a group of stage III patients without any adjuvant treatment who did not develop distant metastases after a minimum follow-up of 5 years, and these patients had a significantly lower “PROM2 IHC score” than the patients in the other two groups. After validation in a larger cohort, this score could be used to identify high and low-risk patients with stage III melanoma more efficiently, and could thus be included in adjuvant clinical trials.

Despite recent improvements in the management of metastatic melanomas, 20 to 40% of patients remain insensitive to immunotherapy or targeted treatments (23, 24), thus challenging clinical practice. Our study opens new perspectives for the use of PROM2 as a potential therapeutic target for the treatment of metastatic melanoma in resort situations.

PROM2 is a membrane glycoprotein and a second member of the prominin family. PROM2 is a paralogue of PROM1 which co-localizes with PROM1 in epithelial cells. PROM1, also called CD133, is a well-known cancer stem-cell marker (25). Cancer stem-cells have been shown to be linked to drug resistance (26–29) tumour invasion and metastatic processes (30–32). Like PROM1, PROM2 is enriched in plasma membrane protrusions in the adult kidney as well as in various other epithelial tissues, and could thus be implicated in cell adhesion, wound healing, and migration (17). Analyses from online databases show a differential mRNA expression of PROM2 in various cancer types, and PROM2 mutations have been reported in skin melanoma (33). However, the role of PROM2 in the metastatic process has not been investigated. Further studies are required to elucidate this role and to see whether or not PROM2 provides stemness properties.

In our study, we identified PROM2 as a biomarker predictive of the risk of distant metastases, particularly brain metastases, among patients with stage III melanoma. Our findings open new perspectives for further studies to validate PROM2 as a useful biomarker in adjuvant clinical trials, and as a potential biotarget for the treatment of metastatic melanoma in resort situations.

List Of Abbreviations

Ct: cycle threshold
IQR: interquartile range
TCGA: The Cancer Genome Atlas
IHC: immunohistochemistry
MRI: magnetic resonance imaging
SEM: standard error of the mean
SD: standard deviation
FDR: false discovery rates
GEO: Gene Expression Omnibus
OR: odd ratio
aOR: adjusted OR
CI: confidence interval
HRa: Hazard ratios
aHR: adjusted HRs

Declarations

Ethics approval and consent to participate

All patients had been informed that a part of their remaining samples could be used for research after diagnosis had been established, and none opposed it. Written informed consent was obtained from each patient. The Clinical-Research-Board-Ethics-Committee approved this study (CPP-Ile-de-France#13218).

Consent for publication

Not applicable.

Availability of data and materials

All data generated or analysed during this study are included in this published article (and its supplementary information files).

Competing interests

The authors declare that they have no competing interests.

Funding

The study was supported by INSERM, University of Paris, and University Paris 13.

Authors’ contributions

GB, AJ and MB conceived and designed the study. PT, BB, JD, CL and SM provided patient clinical data. MB provided patient tumour samples. TTN and MEB carried out the laser-microdissections. GG and JPF analysed the transcriptomic data. TTN and ChL performed the immuno-staining. FP did statistical analyses. AJ, GB and MB provided financial support. AJ and GB provided administrative support. TTN, GB and MB drafted the manuscript. All authors read and approved the final version of the manuscript.

Acknowledgments

We would like to thank Mss S. Leyshon and A. Swaine for revising the English language

References

1. Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017;19(11):1511–21.

2. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011;117(8):1687–96.
3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

4. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23–34.

5. Angeli E, Nguyen TT, Janin A, Bousquet G. How to Make Anticancer Drugs Cross the Blood-Brain Barrier to Treat Brain Metastases. Int J Mol Sci. 2019;21(1).

6. Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018;379(8):722–30.

7. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, et al. Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res. 2009;15(24):7538–46.

8. Niessner H, Forschner A, Klumpp B, Honegger JB, Witte M, Bornemann A, et al. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med. 2013;2(1):76–85.

9. Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, et al. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res. 2006;66(6):3188–96.

10. Chen G, Chakravarti N, Aardalen K, Lazar AJ, Tetzlaff MT, Wubbenhorst B, et al. Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res. 2014;20(21):5537–46.

11. Jilaveanu LB, Parisi F, Barr ML, Zito CR, Cruz-Munoz W, Kerbel RS, et al. PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis. Clin Cancer Res. 2015;21(9):2138–47.

12. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). British journal of cancer. 2005;93(4):387–91.

13. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55(4):611–22.

14. Guan J, Gupta R, Filipp FV. Cancer systems biology of TCGA SKCM: efficient detection of genomic drivers in melanoma. Sci Rep. 2015;5:7857.

15. Jonsson G, Busch C, Knappskog S, Geisler J, Miletic H, Ringner M, et al. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res. 2010;16(13):3356–67.

16. Cirenajwis H, Ekedahl H, Lauss M, Harbst K, Carneiro A, Enoksson J, et al. Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget. 2015;6(14):12297–309.

17. Singh RD, Schroeder AS, Scheffer L, Holicky EL, Wheatley CL, Marks DL, et al. Prominin-2 expression increases protrusions, decreases caveolae and inhibits Cdc42 dependent fluid phase endocytosis. Biochem Biophys Res Commun. 2013;434(3):466–72.

18. Yoshida K, Fujikawa T, Tanabe A, Sakurai K. Quantitative analysis of distribution and fate of human lung cancer emboli labeled with 125I-5-ido-2'-deoxyuridine in nude mice. Surg Today. 1993;23(11):979–83.

19. Maurer C, Tulpin L, Moreau M, Dumitrescu C, de Azambuja E, Paesmans M, et al. Risk factors for the development of brain metastases in patients with HER2-positive breast cancer. ESMO Open. 2018;3(6):e000440.

20. Tas F. Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J Oncol. 2012;2012:647684.
21. Takeuchi H, Fujimoto A, Tanaka M, Yamano T, Hsueh E, Hoon DS. CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res. 2004;10(7):2351–8.

22. Murakami T, Maki W, Cardones AR, Fang H, Tun Kyi A, Nestle FO, et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res. 2002;62(24):7328–34.

23. Manzano JL, Layos L, Buges C, de Los Llanos Gil M, Vila L, Martinez-Balibrea E, et al. Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med. 2016;4(12):237.

24. Gide TN, Wilmott JS, Scolyer RA, Long GV. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. Clin Cancer Res. 2018;24(6):1260–70.

25. Glumac PM, LeBeau AM. The role of CD133 in cancer: a concise review. Clin Transl Med. 2018;7(1):18.

26. Bousquet G, El Bouchtaoui M, Sophie T, Leboeuf C, de Bazelaire C, Ratajczak P, et al. Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer. Oncotarget. 2017;8(21):35205–21.

27. Vama M, Gapihan G, Feugeas JP, Ratajczak P, Tan S, Ferreira I, et al. Stem cells increase in numbers in perinecrotic areas in human renal cancer. Clin Cancer Res. 2015;21(4):916–24.

28. Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sanchez N, Marchesini M, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014;514(7524):628–32.

29. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res. 2009;15(12):4234–41.

30. Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res. 2005;11(3):1154–9.

31. Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res. 2006;12(19):5615–21.

32. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449(7162):557–63.

33. Saha SK, Islam SMR, Abdullah-Al-Wadud M, Islam S, Ali F, Park KS. Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer. J Clin Med. 2019;8(3).
Table 1
Characteristics of the 51 patients in the development cohort with transcriptomic analyses of metastatic lymph nodes

| Variables                                      | N (%)          | Brain metastases (Group 3) N = 19 (37%) | No brain metastasis (Group 1 and 2) N = 32 (63%) | P*  |
|------------------------------------------------|----------------|----------------------------------------|-------------------------------------------------|-----|
| Age (y), mean ± SD                             | 57.8 ± 15.8    | 55.0 ± 15.6                            | 59.5 ± 15.9                                     | 0.3 |
| Gender (women)                                 | 28 (55)        | 11 (58)                                | 17 (53)                                         | 0.7 |
| Initial TNM classification#:                   |                |                                        |                                                 |     |
| IIB                                            | 20 (39)        | 7 (37)                                 | 13 (41)                                         | 0.5 |
| IIIC                                           | 28 (55)        | 10 (53)                                | 18 (56)                                         |     |
| IIID                                           | 3 (6)          | 2 (10)                                 | 1 (3)                                           |     |
| Primary site of melanoma:                      |                |                                        |                                                 |     |
| Head and neck                                  | 5 (10)         | 3 (16)                                 | 2 (6)                                           | 0.6 |
| Trunk                                          | 10 (20)        | 3 (16)                                 | 7 (22)                                          |     |
| Upper limb                                     | 11 (21)        | 5 (26)                                 | 6 (19)                                          |     |
| Lower limb                                     | 23 (45)        | 8 (42)                                 | 15 (47)                                         |     |
| Non-available                                  |                |                                        |                                                 |     |
| Metastatic site:                               |                |                                        |                                                 |     |
| Lung                                           | 24 (47)        | 12 (63)                                | 12 (37.5)                                       | 0.07|
| Bone                                           | 11 (21)        | 8 (42)                                 | 3 (9)                                           | 0.01|
| Liver                                          | 16 (31)        | 8 (42)                                 | 8 (25)                                          | 0.2 |
| Breslow index (mm), median (25th-75th)         | 3.5 (2.0–5.0)  | 3.25 (2.01-7.0)                        | 3.58 (1.42–4.87)                                | 0.4 |
| Ulceration (yes)                               | 18 (41)        | 8 (42)                                 | 10 (31)                                         | 0.7 |
| BRAF status:                                   | 26 (51)        | 9 (47)                                 | 17 (53)                                         | 0.7 |
| BRAF V600E                                     | 25 (49)        | 10 (53)                                | 15 (47)                                         |     |
| Wild type                                      |                |                                        |                                                 |     |

# TNM classification according to 2017 AJCC 8th edition

* Chi square test or Fisher's exact test as appropriate for categorical variables and Student's t-test or Wilcoxon's test for quantitative variables as appropriate
Table 2
Genes differentially expressed in metastatic lymph nodes of patients with versus without brain metastasis

| Gene   | Without brain metastasis (mean) | With brain metastasis (mean) | Fold Change | d-score | P-value |
|--------|--------------------------------|----------------------------|-------------|---------|---------|
| PROM2  | 5.7                            | 7.5                        | 3.3         | 4.6     | 2.1e-05 |
| LRRC2  | 7.4                            | 9.3                        | 3.6         | 4.2     | 2.2e-05 |
| CASC15 | 9.8                            | 11.7                       | 3.6         | 4.2     | 2.2e-05 |
| HMBOX1 | 7.2                            | 9.0                        | 3.5         | 4.1     | 2.2e-05 |
| GPR179 | 5.9                            | 7.7                        | 3.4         | 4.3     | 2.2e-05 |
| CD86   | 9.6                            | 11.4                       | 3.4         | 4.0     | 2.3e-05 |
| RPA4   | 7.1                            | 8.8                        | 3.2         | 4.3     | 2.1e-05 |
| GPR182 | 5.8                            | 7.5                        | 3.1         | 4.4     | 2.1e-05 |
| KRT79  | 5.1                            | 6.7                        | 2.9         | 3.9     | 2.3e-05 |
| PPP6R1 | 8.0                            | 9.4                        | 2.7         | 3.7     | 2.5e-05 |
| BICC1  | 5.1                            | 6.5                        | 2.6         | 4.1     | 2.2e-05 |

Table 3
Univariate and multivariate analyses of factors associated with brain metastasis

| Variables                        | Univariate analysis | P | Multivariate analysis | P |
|----------------------------------|---------------------|---|-----------------------|---|
|                                  | OR [95%CI]          |   | Adjusted OR [95%CI]  |   |
| Metastatic site:                 |                     |   |                       |   |
| Lung                             | 2.86 [0.88–9.25]    | 0.08 | 1.41 [0.27–7.27]   | 0.66 |
| Bone                             | 7.03 [1.57–31.4]    | 0.01 | 16.2 [1.83–395.9]   | 0.02 |
| PROM2 expression, per 1 IQR     | 1.21 [1.03–1.48]    | 0.03 | 1.05 [0.91–1.36]   | 0.62 |
| PROM2 IHC score:                 |                     |   |                       |   |
| Low (< 5)                        | 1 (reference)       | 0.0002 | 1 (reference)      | 0.003 |
| High (≥ 5)                       | 16.0 [4.10–83.1]    |      | 28.2 [4.33–570.7]  |      |
Table 4
Univariate and multivariate analyses of factors associated with mortality in the development and validation cohorts:

| Variables                        | Development cohort (n = 51) |                      |                      | Validation cohort (n = 50) |                      |                      |
|----------------------------------|-----------------------------|----------------------|----------------------|---------------------------|----------------------|----------------------|
|                                  | Univariate analysis         | Multivariate analysis|                      | Univariate analysis       | Multivariate analysis|
|                                  | HR [95%CI]                  | aHR [95%CI]          |                      | HR [95%CI]               | aHR [95%CI]          |
| Age (y), mean ± SD               | 1.01 [0.98–1.03]            | 1.01                 | 0.37                 | 0.98 [0.96–1.01]          | 0.26                 |
| Gender (women)                   | 0.94 [0.46–1.93]            | 0.94                 | 0.88                 | 0.82 [0.39–1.75]          | 0.62                 |
| Initial TNM classification       |                             |                      |                      |                           |                      |
| IIIB                             | 1 (reference) 1.22 [0.57–2.60] | -                    | -                    | 1 (reference) 1.12 [0.53–2.34] | -                  |
| IIIC                             | 2.60                        | -                    | -                    | 0.86 [0.11–6.58]          | -                   |
| IIID                             | 7.26 [1.85–28.4]            | -                    | -                    | 0.42 [0.10–1.64]          | -                   |
| Primary site of melanoma         | 1 (reference) 0.91 [0.26–3.15] | 0.49                 |                      | 1 (reference) 0.42 [0.10–1.64] | 0.20 |
| Head and neck                    | 0.48 [0.13–1.75]            |                      |                      | 0.80 [0.19–3.26]          | -                   |
| Trunk                            | 0.46 [0.15–3.15]            |                      |                      | 1.08 [0.30–3.86]          | -                   |
| Upper limb                       | 1.44                        |                      |                      | -                         | -                   |
| Lower limb                       | 0.46 [0.05–4.45]            |                      |                      | -                         | -                   |
| Unknown                          |                             |                      |                      |                           |                      |
| Metastatic site:                 | 2.61 [1.28–5.34] [2.86–39.9] | 2.61                 | 0.008                 | 5.20 [2.39–11.3]          | < 0.0005             |
| Brain                            | 3.82 [1.78–8.18]            | 3.82                 | 0.08                 | 2.36 [1.13–4.96]          | 0.01                 |
| Lung                             | 2.00 [0.91–4.36]            | 2.00                 | 0.09                 | 2.50 [1.17–5.37]          | 0.05                 |
| Bone                             | 1.85 [0.90–3.79]            | 1.85                 |                      | 2.07 [0.99–4.31]          | -                   |
| Variables | Development cohort (n = 51) | Validation cohort (n = 50) |
|-----------|-----------------------------|---------------------------|
| Breslow index (mm), per 1 IQR of more | 1.19 [1.04–1.36] | 0.93 [0.82–1.06] |
| Ulceration (yes) | 2.75 [1.26–6.00] | 1.19 [0.53–2.65] |
| BRAF status: BRAF V600E (yes) | 1.49 [0.73–3.04] | 1.49 [0.65–3.42] |
| PROM2 mRNA expression, per 1 IQR of more | 1.02 [0.99–1.05] | 1.16 [1.03–1.31] |
| PROM2 IHC score: High (≥ 5) | 2.41 [1.16–5.03] | 3.95 [1.14–13.7] |

Interaction terms:

| Interaction terms | Development cohort (n = 51) | Validation cohort (n = 50) |
|-------------------|-----------------------------|---------------------------|
| Lung metastases x PROM2 IHC score ≥ 5 | 0.12 [0.02–0.64] | 0.21 [0.04–1.10] |
| Brain metastases x PROM2 IHC score ≥ 5 | - | 0.06 |

*Univariate and multivariate Cox proportional hazard regression models were run with the sample of deceased patients. The assumptions of the model were verified. Hazard ratios (HRs) for continuous variables were expressed per 1 SD or 1 interquartile range (IQR) as appropriate. Variables yielding P values under 0.2 in the univariate analysis were considered for inclusion in the multivariate analysis. A stepwise selection process of the lowest P values was used for the multivariate analysis, also using interaction terms.

Figures
Figure 1

Survival analyses according to presence or absence of brain metastases of the development cohort. A. The groups in the development cohort: patients without brain metastases include Group 1 and Group 2. Group 3 includes patients with brain metastases. B. Survival according to brain metastasis status in the series of 51 patients with transcriptomic analyses. The median overall survival is significantly shorter among patients with brain metastases than among those without.
Figure 2

PROM2 mRNA expression, “PROM2 IHC score” in metastatic lymph nodes and survival data in the development cohort. A. PROM2 mRNA expression is significantly higher in metastatic lymph nodes from patients with brain metastases than in those from patients without brain metastases (p < 0.05). B. Using immuno-staining on metastatic lymph nodes, the mean “PROM2 IHC score” is significantly higher among patients with brain metastases than among those without (p<0.05). C. Survival according to the “PROM2 IHC score” level in the development cohort of 51 patients. A “PROM2 IHC score” ≥ 5 is significantly associated with a shorter survival.
Figure 3

PROM2 expression and survival data according to sub-groups in the development cohort A. Group 1 includes patients with only regional lymph node metastases; Group 2 includes patients without brain metastases but with other distant metastatic localizations; Group 3 includes patients with brain metastases. B. PROM2 mRNA expression and PROM2 mean score in the 3 different groups. PROM2 mRNA expression and PROM2 mean score are gradually and significantly different in the 3 groups. C. Survival curves according to the 3 different groups. *p<0.05, **p<0.01

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.
• SupplementaryTable2.doc
• SupplementaryTable1.doc
• SupplementaryFigurelegends.docx
• SupplementaryFigure3.jpg
• SupplementaryFigure2.jpg
• SupplementaryFigure1.pdf
• SupplementaryMaterialsandMethods.docx